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ABSTRACT The human ETS2 gene, a member of the ETS
gene family, with sequence homology with the retroviral ets
sequence of the avian erythroblastosis retrovirus E26 is located
on chromosome 21. Molecular genetic analysis of Down syn-
drome (DS) patients with partial trisomy 21 allowed us to
reinforce the supposition that ETS2 may be a gene of the
minimal DS genetic region. It was originally proposed that a
duplication of a portion of the DS region represents the genetic
basis of Alzheimer disease, a condition associated also with DS.
No evidence of either rearrangements or duplications ofETS2
could be detected in DNA from fibroblasts and brain tissue of
Alzheimer disease patients with either the sporadic or the
familiar form ofthe disease. Thus, an altered ETS2 gene dosage
does not seem to be a genetic cause or component of Alzheimer
disease.
Two human diseases, Down syndrome (DS) and Alzheimer
disease (AD), in some way interrelated (see below), represent
a puzzle for geneticists. DS, is the most common inherited
disease, occurring once in 1000 live births (1). The majority
of DS patients present one extra chromosome 21 (2) as a
result of a nondisjunction event in one of the meiotic stages.
Thus, for more than 20 years, the imbalance of the entire
extra set of chromosome 21 genes has been thought to be the
cause of the abnormal development, the dismorphic features,
and the mental retardation observed in the disease (3-6). Few
DS cases present with the trisomy ofjust a small portion of
chromosome 21. This allowed the definition that only the
trisomy of the distal portion of the chromosome may be
sufficient for generating the DS phenotype (7-12). In this
region 20-100 genes may be present. We do not know if all
or just a few of them are crucial for the appearance of the
syndrome. Moreover, it is not clear whether the genes that
cause the prenatal abnormal development ofDS are the same
genes that produce a number of postnatal abnormalities often
developed by DS patients. Among these, the most commonly
recorded anomalies are the high susceptibility to infections;
the predisposition to leukemia in DS children; the premature
aging; and the development of the neurological signs of AD
(13, 14). AD, a degenerative disorder of the central nervous
system, is not limited to DS individuals. AD causes profound
mental and physical disability and is the fourth leading cause
of death among the population in middle to late adult life (15).
Two forms of AD are known: one rare familial form caused
by an autosomal dominant gene defect and the most common
sporadic form with unknown, possibly genetic, etiology. The
occurrence of AD-like disease in the already mentally im-
paired DS patients originated the theory that the imbalance
(trisomy?; deregulation?) of one or more genes of the DS
minimal genetic region could be implicated in the origin ofAD
(16). The recent identification ofthe genetic locus causing the
familial AD on chromosome 21q21 (17), far outside the DS
region, would not exclude the existence of other gene(s) for
the sporadic form in other sites ofchromosome 21 or on other
chromosomes. Actually, the recent literature is rich in
reports that implicate in sporadic AD "this or that" gene on
chromosome 21. Scattered microduplications of the chromo-
some have been proposed as an explanation ofincreased gene
dosage for the superoxide dismutase (SOD!) gene (18), the
protooncogene ETS2 (19, 20), and the amyloid ,8-protein gene
APP (21) as measured in the genome of AD patients. These
findings prompted us to investigate this issue as far as the
ETS2 gene is concerned. The human ETS2 gene, first iden-
tified in our laboratory (22) as a member of a family of genes
related to the v-ets gene of the avian erythroblastosis retro-
virus E26, is located on chromosome 21 (23, 24) and is highly
conserved, being found from lower organisms, like Drosophila
(25) and sea urchin (26), to man (22); this gene codes for a
nuclear 56-kDa protein (27) that might play a critical role in
controlling some step of the signaling transduction pathway.
Thus, ETS2, as other genes with homology with viral onco-
genes, might well be instrumental in regulating cellular growth
and differentiation as well as organismal development.
MATERIALS AND METHODS
Patient Material. Fibroblasts from different patients with
various chromosome aneuploidies (described in detail in Fig.
1) were analyzed. Cases T-1 and T-2 presented complete
trisomy 21; C-1 (28, 29), C-2 (30), C-3 (10), and C-4 (10)
presented partial trisomy 21: C-5 (30), C-6 (31), and C-7 (31)
presented partial monosomy 21; M-1 (32) and M-2 (33)
presented complete monosomy 21. Seven fibroblast strains
were derived fromAD patients. Six (A-1 to A-6) were derived
from familial AD patients. A-7 was derived from a sporadic
AD patient ascertained at the autopsy. All fibroblast strains,
including fibroblasts from two normal individuals, were
cultured in minimal essential medium (MEM) containing 10%
(vol/vol) fetal calf serum. Twenty brain specimens (A-8 to
A-27), all from sporadic AD patients confirmed at autopsy,
were also analyzed. (The AD specimens were obtained from
the Brain Bank of the Douglas Hospital Research Center,
Montreal, Canada.)
Gene Dosage Analysis. Genomic DNA was extracted from
cultured cells and brain specimens as described (34). Aliquots
of 10 ,ug of genomic DNA were digested with various
restriction enzymes as indicated by the supplier (Boehringer
Mannheim). Agarose gel electrophoresis, Southern blotting,
hybridization, and stringency of the washing conditions have
been described in detail elsewhere (34). The probes used
included a 1.0-kilobase (kb) genomic fragment of ETS2 (22),
a few chromosome 21 anonymous probes mapping proxi-
Abbreviations: DS, Down syndrome; AD, Alzheinier disease;
RFLP, restriction fragment length polymorphism.
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FIG. 1. Fibroblast strains presenting various chromosome 21 aneuploidies were derived from patients C-1 to C-7, M-1, and M-2 with the
outlined karyotypic and phenotypic features.
mally or distally to ETS2 (35, 36), and a 0.45-kb anonymous
DNA fragment mapping on chromosome 22 (N.S., unpub-
lished data).
Allelic dosage was evaluated by visual inspection of the
intensity of the allelic fragments detected by the polymorphic
probes within the same lane of autoradiograms of Southern
blots. Quantitative densitometric analysis was performed on
autoradiograms of Southern blots containing both control
(diploid) and test DNAs. The ratio between the hybridization
signals of the EcoRI 3.8-kb fragment detected by the ETS2
probe and the EcoRI 3.2-kb fragment detected by the refer-
ence probe on chromosome 22 was calculated for each
sample in the same Southern blot to correct forDNA loading.
Southern blot filters were first hybridized to the ETS2 probe,
freed of the probe, and hybridized to the reference 0.45-kb
probe. The densitometric tracing of autoradiograms were
performed with a laser LKB Ultroscan densitometer. The
peak areas corresponding to each hybridization signal were
calculated by electronic integration.
RESULTS
First we assessed whether ETS2 was always in three copies
in the putative DS region by analyzing directly (DNA of DS
cases C-1, C-2, and C-3) or indirectly (case C-6, brother of
two DS patients) a few ofthese regions (Fig. 1). We measured
the ETS2 gene content in these patients' DNAs by t sing
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either a Taq I restriction fragment length polymorphism
(RFLP) for a 1.0-kb ETS2 sequence (34) or quantitative
densitometry. These experiments also served to establish the
best possible panel of control DNAs with one, two, or three
ETS2 copies for assessing for ETS2 dosage in cells of AD
patients.
RFLP analysis of human genomic DNA using the Taq I
enzyme and a genomic 1.0-kb ETS2 probe evidenced one
allele (Al) of 4.0 kb and a second allele (A2) of 1.2 kb as well
as a constant band of 2.0 kb (34). Thus, using this RFLP, we
could easily distinguish trisomy versus disomy whenever
there was heterozygosity, since by visual inspection a dif-
ferent ratio of one allele versus the other was evident (Figs.
2 and 3). As an example, clearly, three alleles, Al A2 A2, were
observed in one DS patient with partial trisomy 21 (C-1) Fig.
2, lanes 4 and 5), and only two alleles, Al A2, were observed
in heterozygous AD fibroblasts (patients A-2 and A-5, re-
spectively) (Fig. 2, lanes 9 and 10). Brain DNAs from 20
patients with sporadic AD were also analyzed. Heterozygos-
ity for Taq I ETS2 polymorphism was observed in 14 cases.
A typical blot is shown in Fig. 3, where one copy ofeach allele
Al and A2 was detected in heterozygous patient DNAs (lanes
1 to 4). Our observations exclude the presence ofthree copies
of ETS2 also in all the other 10 heterozygous patients we
analyzed (data not shown). The overall RFLP analysis was
indicative of (i) unequivocal association between three cop-
ies ofETS2 and the extra chromosome 21 material causing DS
8 9 10 11
-4.0 kb Al
40 4_ to *
-1.2 kb A2
-4.0 kb
__ _
*
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FIG. 2. RFLP analysis of human genomic DNA using the Taq I restriction endonuclease and a 1.0-kb ETS2 genomic probe. Two alleles,
Al (4.0 kb) and A2 (1.2 kb), are identified, as well as a constant band (*) of 2.0 kb. The allelic ratio allows us to distinguish: trisomic heterozygous
cells with an AIAIA2 genotype (lanes 3 and 11) and AIA2A2 genotype (lanes 4, 5, and 8), disomic heterozygous cells with an AIA2 genotype
(lanes 1, 2, 9, and 10), and homozygous cells with AIAI and A2A2 genotypes (lanes 7 and 6, respectively). In particular, lanes 4 and 5 represent
the RFLP pattern found in DNA of the DS patient with partial trisomy (C-1), thus showing the presence of three copies of the ETS2 gene, and
lanes 9 and 10 represent the RFLP pattern found in DNA of AD patients A-2 and A-5, showing the presence of two copies of the ETS2 gene.
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FIG. 3. Taq I ETS2 RFLP of six DNA samples from the brains of
autoptically ascertained AD patients presenting the sporadic form.
The visual inspection of Al (4.0 kb) and A2 (1.2 kb) alleles clearly
shows two copies of the ETS2 gene in DNAs in lanes 1-4. Lanes S
and 6 contain DNA of two homozygous patients for whom RFLP
analysis was not conclusive. *, Constant band of 2.0 kb.
in patient C-1 and (ii) presence of two copies of ETS2 in all
of the heterozygous AD patients.
We further assessed the ETS2 dosage in all fibroblast
DNAs, (including all of the chromosome 21 aneuploidies and
the AD cases) by quantitative densitometric analysis of
Southern blots. As a control, normal diploid fibroblast DNA
was used. The ratio between the hybridization signals of an
EcoRI 3.8-kb fragment detected by the ETS2 probe and an
EcoRI 3.2-kb fragment detected by the reference probe on
control chromosome 22 was calculated for each test and
control sample in five independent lanes in the same South-
ern blot to correct for DNA loading. The densitometric
tracings of autoradiograms were performed with a laser LKB
Ultroscan densitometer. The peak areas corresponding to
each hybridization signal were calculated by electronic inte-
gration. In all cases, the testDNA was compared to the DNA
from disomic cells within the same Southern blot. The results
ofthis analysis are presented in Table 1. The means, SDs, and
SEMs were calculated on the basis of the five independent
ratios between ETS2 and the reference probe obtained on
each of the test DNA and control DNA. The statistical
significance of the comparison of test DNA versus control
DNA was calculated by the student t test (37). From this
analysis it was possible to interpret the "probable" copy
number ofETS2 gene in each case, except for two cases, C-6
and A-4 (this is the reason for the question mark), which had
P values of 0.0002 and 0.0015, respectively. The entire set of
36 means was further examined by analysis of variance,
followed by the Student-Newman-Keuls multiple compari-
son test at the 0.05 probability level (37). This test identified
a distinct set of three homogeneous test samples (M-1, M-2,
and C-5) with mean ratios ranging from 0.524 to 0.624, which
would be interpreted as having one copy of ETS2, and a
second distinct set of five homogeneous test samples (T-1,
T-2, C-1, C-2, and C-3) with mean ratios ranging from 1.407
to 1.516, which would be interpreted as having three copies
of the gene (Fig. 4). The means of the remaining 10 test
samples fell in a middle ground, having ratios ranging from
0.909 to 1.180, the same approximate range as those con-
taining all of the 18 controls obtained from two individuals.
In the student-Newman-Keuls test, the difference between
C-6 and its control no longer remained significant, thus
leading to the interpretation of two ETS2 copies. However,
the difference between A-4 and its control remained signifi-
cant, although only marginally at the 0.05 probability level.
To complement the information obtained from densito-
metry, RFLP analysis using polymorphic chromosome 21
sequences, chosen for loci proximal or distal to ETS2
according to the genetic map (35, 36), was also performed. In
cases of heterozygosity for the alleles detected by these
polymorphic probes, the analysis confirmed the disomy or
Table 1. Quantitative densitometry of probe hybridization for
cells of patients with various chromosome 21 aneuploidies
and AD
Subject Mean SD SEM P ETS2
C 1.015 0.089 0.039 0.0001 3
T-1 1.409 0.089 0.039
C 1.015 0.066 0.029 <0()(X1 3
T-2 1.407 0.076 0.034
C 1.035 0.121 0.054 0.0003 1
M-1 0.624 0.089 0.039
C 1.050 0.093' 0.041 000
M-2 0.575 0.027 0.012 0.0002 1
C 0.953 0.133 0.059 000
C-1 1.515 0.114 0.051 0.0001 3
C 1.087 0.082 0.037
C-2 1.471 0.067 0.030 <0.0001 3
C 1.076 0.110 0.049 0.0014 3
C-3 1.444 0.029 0.013
C 1.107 0.078 0.035 0.96 2
C-4 1.105 0.080 0.035
C 0.944 0.105 0.047
C-5 0.523 0.084 0.037 0.0001 1
C 1.102 0.047 0.021 0.0002 2?
C-6 0.939 0.029 0.013
C 0.922 0.033 0.014 0.88 2
C-7 0.918 0.045 0.020
C 0.884 0.023 0.010 0.20 2
A-1 0.955 0.182 0.045
C 1.186 0.051 0.023 0.91 2
A-2 1.179 0.119 0.053
C 1.008 0.089 0.037 0.059 2
A-3 1.103 0.044 0.020
C 0.927 0.099 0.044 0.0015 2?
A-4 1.166 0.053 0.023
C 0.871 0.095 0.042 0.46 2
A-5 0.908 0.050 0.022
C 0.975 0.146 0.065
A-6 1.109 0.047 0.021 0.087 2
C 1.052 0.070 0.031
A-7 1.088 0.043 0.019 0.36 2
Ratio of the densitometric readings of the EcoRI 3.8-kb band
detected by the ETS2 probe and the EcoRI 3.2-kb band ofa reference
probe on chromosome 22 was evaluated in five independent exper-
iments for each test DNA and for each control (C) DNA. Test DNA
(five lanes) and control DNA (five lanes) were compared in the same
Southern blot. The mean, SD, and SEM were calculated for each test
and control DNA on five ratio values. By using the t test, the
probability (P) that the difference between the mean values of test
and control samples would be due to chance was calculated and the
probable number of ETS2 gene copies was deduced in each case,
with the exception of subjects C-6 and A-4 (see question marks).
the trisomy of the regions adjacent to ETS2 (data not shown).
For instance, in patient C-1 the trisomy for the region
surrounding ETS2 was reaffirmed from the observation ofthe
allelic ratio detected by the D21S23 probe distal to ETS2 (35)
(Fig. 5, lane 1), when compared to the heterozygous RFLP
pattern ofa complete trisomy 21 (lane 2) and a normal control
(lane 3), respectively. In each patient the additional RFLP
analysis helped to accept with confidence the conclusions
relative to the ETS2 dosage deduced from quantitative
densitometry-the obligate technique whenever there was a
homozygous condition for this locus.
DISCUSSION
The supposition that ETS2 located at the 21q22 band (23, 24)
might be an element of the putative DS genetic region (7-12)
is reinforced by the present findings. ETS2 was found in three
copies in all the partial trisomies 21 associated with DS
phenotype that we analyzed. In particular, ETS2 was found
Genetics: Sacchi et al.
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FIG. 4. The means reported in Table 1 of the 18 patients and 18
matching controls (from two normal individuals) were examined by
analysis of variance followed by the Student-Newman-Keuls mul-
tiple comparison test at the probability level of 0.05. The controls are
marked by an asterisk (e.g., C-1* is the control of C-1). A set of 3
homogeneous test samples (M-1, M-2, and C-5) would be interpreted
as having one ETS2 gene; a second distinct set of 5 test samples (T-1,
T-2, C-1, C-2, and C-3) would be interpreted as having three copies
of ETS2. The remaining 10 samples presented ratios in the approx-
imate range containing all of the 18 control samples and would be
interpreted as having two ETS2 gene copies.
in triplicate when the trisomic region was barely visible at the
cytogenetic analysis, as in patient C-1. Recent reports
claimed that an extra copy of the ETS2 gene was present in
the DNA of AD patients. These reports, based on quantita-
tive densitometry (19) and in situ hybridization (20), were in
line with the proposed hypothesis that trisomy of one (or
more) gene(s) in the DS region could be the cause ofAD (16).
On the contrary, the results of our analysis showed that two
copies of ETS2 are commonly found in both familial and
sporadic forms of AD. Even if the existence of genetic
heterogeneity among various AD patients cannot be ex-
cluded, the most probable reason for the difference between
our results and the results of other reports (19, 20) lies in the
intrinsic limitations of the techniques currently available for
gene dosage studies. In contrast to RFLP analysis, which is
the most reliable technique, quantitative densitometry was,
in our experience, quite tricky in distinguishing between two
1 2 3
1.4 kb- woo
1.2kb- M
FIG. 5. Southern blot analysis of genomic DNA of fibroblasts
from DS patient C-1 with dup(21)q(22) digested with EcoRI and
probed with the pPW244D sequence for the D21S23 locus distal to
ETS2. The allelic ratio of C-1 DNA shows the presence oftwo copies
ofthe 1.4-kb allele and one copy of the 1.2-kb allele (lane 1), an RFLP
pattern of heterozygous trisomic cells with the opposite allelic ratio
(lane 2), and a RFLP pattern of heterozygous disomic cells with the
same allelic ratio (lane 3).
and three gene copies in some cases. This point was clear, for
instance, in cases C-6 and A-4 (Table 1). In these two cases
we had to rely on additional RFLP analysis for loci adjacent
proximally or distally to ETS2 to get an idea about the dosage
of the region containing ETS2, and we could not conclude for
the most "probable" ETS2 copy number only on the basis of
densitometric measurements (Table 1, see question marks).
Of course, additional RFLP analysis would not be helpful to
assess the dosage for very minute duplications, involving for
instance, just one gene. Also, the in situ hybridization
technique chosen by other authors (20) for gene dosage
studies can have posed some limitations when used to assess
the ETS2 content. This limitation consists in the existence of
a closely related ETS2 gene, ERG (38), proximal to ETS2 on
chromosome 21q22. Given that in AD cells, as in other
pathological conditions, the condensation status of chromo-
somes may differ from that of normal control cells, and
assuming that a probe showing homology with both ETS2 and
ERG was used (20), the appearance of two hybridization
peaks, one for ERG and one for ETS2, could have been
interpreted as a rearrangement-i.e., duplication of ETS2.
The existence of duplications in AD DNAs for genes
different from ETS2 was excluded in other investigations.
Duplication (trisomy) of genes on chromosome 21, like the
amyloid p-protein gene APP (21) and the superoxide dismu-
tase gene SOD] (18), have been described in some AD
patients but never confirmed in several laboratories in dif-
ferent patients (39-41). Seemingly, even if genetic compo-
nents may well be involved in the etiology of AD, they are
very unlikely to be microduplications of ETS2 and amyloid
,8-protein genes. This conclusion does not rule out that
chromosome 21 genes (e.g., the just-mentioned amyloid
p-protein gene) may in other ways contribute to the disease.
AD might have a complex genetic etiology. Even now, more
than one gene seems at work in AD-the familial AD gene
distinct (42) from the amyloid ,-protein gene and the T-
protein gene (43).
The search for other genes that may be implicated in AD
should not be restricted only to chromosome 21. It has been
proposed (44) that recently evolved genes responsible for the
most elaborated regions of human brain may be the ones that
when mutated or deregulated confer AD. According to this
hypothesis, AD, which does not find a naturally occurring
analog in animals (45) and has a predilection for the associ-
ation neocortices, some parts of the hyppocampal forma-
tions, the nucleus basalis of Meynert, and the amygadala (44)
is a "phylogenetic" disease. In view of this attractive
hypothesis, it is more likely that genes generated through
recent molecular evolution should contribute to AD. On this
ground, ETS2 having features of a highly conserved gene
should be extraneous to this pathology. Indeed, ETS2 is
found from invertebrates (25, 26) to humans (22) and shares
sequence homology even with some yeast cell-cycle genes
(46). On the other hand, the considerations that make
improbable a relationship between ETS2 and AD may sup-
port ETS2 as a possible genetic element of an "ontogenetic"
anomaly like DS. ETS2, as proposed for other oncogenes,
might be critical for normal developmental processes. In this
context, an overproduction of otherwise normal ETS2 pro-
teins (27) could alter the delicate balance of biochemical
pathways or could create interferences with cell-cell inter-
action processes necessary for a proper fetal development,
thus causing some of the multiple abnormalities of DS. This
hypothesis can be partially tested by introducing ETS2 in
transgenic mice. Comparative human and murine genetic
maps showed that ETS2 belongs to the group of genes on
chromosome 21 that are present on mouse chromosome 16
(23, 47). Interestingly, a few DS features are present in mice
with trisomy 16 or mosaics of trisomy 16 (48-50). Recently,
it has been shown that transgenic mice carrying an extra copy
Test Samples
|C-5IM-1|
Control Samples
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of individual chromosome 21 genes can be constructed (51).
These transgenic mice can be used to engineer mice carrying
other human chromosome 21 genes, individually or in sets of
two or more. From these animal models we should learn
whether, indeed, an extra dosage of ETS2 is responsible for
some of the major dismorphic features of DS, or whether it
is simply predisposing to postnatal DS conditions like the
increased susceptibility to leukemia (52).
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